Bictegravir is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
Bictegravir (BIC) inhibits the strand transfer activity with an IC50 of 7.5± 0.3 nM. Relative to its inhibition of strand transfer activity, Bictegravir is a much weaker inhibitor of 3′-processing activity of HIV-1 IN, with an IC50 of 241±51 nM. Bictegravir enhances the accumulation of 2-LTR circles ~5-fold relative to the mock-treated control and reduces the amount of authentic integration products in infected cells by 100-fold. Bictegravir potently inhibits HIV-1 replication in both MT-2 and MT-4 cells with EC50s of 1.5 and 2.4 nM, respectively. Bictegravir exhibits potent antiviral effects in both primary CD4+ T lymphocytes and monocyte-derived macrophages, with EC50s of 1.5±0.3 nM and 6.6±4.1 nM, respectively, which are comparable to values obtained in T-cell lines.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
University of Nebraska|Gilead Sciences
October 9, 2019
Thomas Jefferson University|University of Maryland, College Park|Indiana University Health|The Brooklyn Hospital Center|University of Illinois at Chicago|Nova Southeastern University|University of California, San Francisco
September 1, 2019
University of Colorado, Denver|Gilead Sciences
March 1, 2020
Vancouver Infectious Diseases Centre
Human Immunodeficiency Virus I Infection|Drug Use
November 26, 2018
Cristina Mussini|University of Modena and Reggio Emilia
Azienda Ospedaliera Universitaria Senese|Catholic University of the Sacred Heart|Ospedale Policlinico San Martino|Azienda Ospedaliera San Paolo|Ospedale Amedeo di Savoia
January 29, 2020
University of Southern California
Acute HIV Infection
October 14, 2019
April 17, 2015
Fenway Community Health
January 24, 2019
Midland Research Group, Inc.|Gilead Sciences
Human Immunodeficiency Virus
March 1, 2018